Frank A Robey8729 Ridge St, Bethesda, MD 20817

5444150, Aug 22, 1995

Nov 19, 1993

8/154786

John K. Inman - Bethesda MD
Frank A. Robey - Bethesda MD

The United States of America as represented by the Department of Health
and Human Services - Washington DC

A61K 3702
C08G 6348

530300

A new amino acid derivative, N. sup. alpha. -tert-butoxycarbonyl-N. sup. e -(N-bromoacetyl-. beta. -alanyl)-L-lysine (BBAL), has been synthesized as a reagent to be used in solid-phase peptide synthesis for introducing a side-chain bromoacetyl group at any desired position in a peptide sequence. The bromoacetyl group subsequently serves as a sulfhydryl-selective cross-linking function for the preparation of cyclic peptides, peptide conjugates and polymers. BBAL residues are stable to final HF deprotection/cleavage. BBAL peptides can be directly coupled to other molecules or surfaces which possess free sulfhydryl groups by forming stable thioether linkages. Peptides containing both BBAL and cysteine residues can be self-coupled to produce either cyclic molecules or linear peptide polymers. Such peptide derivatives are useful in preparing potential peptide immunogens, vaccines and therapeutics, and for substances such as peptides linked to polymers, plastics, enamels and ceramics.

5750332, May 12, 1998

Jan 19, 1995

8/375100

Frank A. Robey - Bethesda MD

The United States of America as represented by the Secretary of the
Department of Health and Human Services - Washington DC

C12Q 170
A61K 3810

435 5

The present invention relates to synthetic peptide analogues useful as therapeutic agents, immunogens or for the diagnosis of disease. In particular, it relates to peptide multimers which maintain the conformation of the native proteins from which they are derived. Peptomers constructed from peptides derived from gp120 of the human immunodeficiency virus are exemplified.

5092876, Mar 3, 1992

Aug 30, 1989

7/400870

Subhash Dhawan - Gaithersburg MD
Frank A. Robey - Bethesda MD

The United States of America as represented by the Department of Health
and Human Services - Washington DC

A61F 202
A61K 3702

623 11

The present invention is directed to a human serum amyloid P component peptide sequence having 12 ammo acid residues and having the sequence identified as Glu-Lys-Pro-Leu-Gln-Asn-Phe-Thr-Leu-Cys-Phe-Arg. The invention is also directed to fragments of the above peptide. Two fragments useful in the present invention have the sequence Phe-Thr-Leu-Cys-Phe-Arg and Leu-Cys-Phe-Arg. The above peptides are useful for attaching cells to substrates such as ceramics, tissue culture, dishes, polymers or enamels and thus are useful as research tools for studying particular cells. The above peptides are also useful in vivo as artificial organ replacements which attach surrounding natural cells.

5286846, Feb 15, 1994

Jun 14, 1991

7/715650

John K. Inman - Bethesda MD
Frank A. Robey - Bethesda MD

The Government of the United States of America as represented by the
Dept. of Health and Human Services - Washington DC

A61K 3702
C08G 6348

530300

A new amino derivative, N. sup. alpha. -tert-butoxycarbonyl-N. sup. epsilon. -(N-bromoacetyl-. beta. -alanyl)-L-lysine (BBAL), has been synthesized as a reagent to be used in solid-phase peptide synthesis for introducing a side-chain bromoacetyl group at any desired position in a peptide sequence. The bromoacetyl group subsequently serves as a sulfhydryl-selective cross-linking function for the preparation of cyclic peptides, peptide conjugates and polymers. BBAL residues are stable to final HF deprotection/cleavage. BBAL peptides can be directly coupled to other molecules or surfaces which possess free sulfhydryl groups by forming stable thioether linkages. Peptides containing both BBAL and cysteine residues can be self-coupled to produce either cyclic molecules or linear peptide polymers. Such peptide derivatives are useful in preparing potential peptide immunogens, vaccines and therapeutics, and for substances such as peptides linked to polymers, plastics, enamels and ceramics.

5066716, Nov 19, 1991

Dec 13, 1988

7/283849

Frank A. Robey - Bethesda MD
Raymond L. Fields - Mount Airy MD
Wolfgang Lindner - Graz, AT

The United States of America as represented by the Secretary of the
Department of Health and Human Services - Washington DC

A61K 3702
C08G 6344
C08G 6391
C08G 6900

525 541

A method to incorporate bromoacetyl and chloroacetyl moieties on amino groups of synthetic peptides using a standard program with an automated peptide synthesizer has been developed. The bromoacetyl and chloroacetyl-derivatized peptides react well with sulfhydryl-containing proteins and with peptides containing cysteine residues. Autopolymerization or cyclization occurs by reaction of the free sulfhydryl of cysteine in a peptide with the bromoacetyl group (or chloroacetyl group) and reactions can generally be controlled by controlling the concentrations of starting peptide in neutral pH buffers. Analytical methods for evaluating the polymers or cyclized peptides include gel filtration chromatography, reverse phase HPLC, SDS-PAGE and amino acid analysis where the degree of reaction can be evaluated by quantifying the amount of S-carboxymethylcysteine formed after HCl hydrolysis. N-bromoacetyl-derivatized peptides are useful as reagents for potential peptide immunogens, vaccines and therapeutics, and for substances such as peptides linked to polymers, plastics, enamels, and ceramics.

5092885, Mar 3, 1992

Nov 16, 1988

7/272165

Yoshihiko Yamada - Silver Spring MD
Jeannette O. Graf - Glen Oaks NY
Yukihide Iwamoto - Higashi, JP
Frank Robey - Bethesda MD
Hynda K. Kleinman - Bethesda MD
Makoto Sasaki - Wheaton MD
George R. Martin - Bethesda MD

The Government of the United States of America as Represented by the
Secretary of the Department of Health and Human Services - Washington DE

A61F 0000

623 11

Peptides with laminin activity are provided as follows: tyrosine-isoleucine-glycine-serine-arginine; proline-aspartine-serine-glycine-arginine; and cysteine -aspartate-proline-glycine-tyrosine-isoleucine-glycine-serine-arginine. These peptides block angiogenesis, alter the formation of capillary structures by endothelial cells, prevent the formation of excess blood vessels in tissues, and inhibit in vivo tumor cell colonization of tissues.

6086881, Jul 11, 2000

May 15, 1998

9/079374

Andreas Frey - Muenster, DE
Marian R. Neutra - Sherborn MA
Frank A. Robey - Bethesda MD

Children's Medical Center Corp. - Boston MA

A61K 39385
A61K 3800
A61M 3614
C07K 500

4241941

The present invention is a spatially aligned conjugated composition which comprises at least one chemically modified substance which is immunologically representative of a prechosen infectious agent and provides a chemical constituent for entering into and forming a thioether bond; a plurality of chemically substituted metallic oxide particles which range from about 10-10,000 nanometers and are able to enter into a thioether bond and covalent linkage; and at least one thioether bond and linkage joining the metallic oxide particles in a controlled and spatially aligned manner to the antigen or hapten. The conjugated composition may be alternatively employed as an immunogen; as a vaccine; as a diagnostic tool and reactant; and as an analytical material suitable for testing the pharmacological activity of new compounds.

2014024, Sep 4, 2014

Dec 19, 2013

14/134378

Frank A. Robey - Bethesda MD, US

A61K 39/39
A61K 39/02
A61K 39/145

4242041, 556173, 556 10, 556405, 556425, 556413, 4242781, 534 15, 4242771, 4242341, 4242741

Adjuvant and immunological vaccine compositions comprising modified, cationic metal oxides are disclosed, including methods of making modified, cationic metal oxides and methods of using the modified metal oxides in vaccine formulations and regimens.